Have your say on pharmacist prescribing: PBA consultation now open

The Pharmacy Board of Australia (PBA) is currently consulting on a proposed national standard for pharmacist prescribing. This is a significant regulatory proposal that could reshape prescribing responsibilities across Australia and has important implications for patient safety, continuity of care, and clinical governance.  

Recently, we ran a survey for our members to better understand your views on pharmacy prescribing. Our response to the consultation will reflect what we have heard.  

But we also encourage you to engage with the consultation directly and ensure the medical profession’s perspective is clearly represented. 

Read the consultation documents on the Pharmacy Board website  

Why this matters 

• The proposed changes introduce a national endorsement model for pharmacist prescribing. 

• Pharmacists are already prescribing in some jurisdictions, with this proposal aiming to standardise education and training requirements nationally. 

• The consultation will inform future regulatory settings that affect prescribing, diagnosis, and models of care. 

How you can participate 

The Pharmacy Board is seeking feedback by close of business on 15 June 2026. 

You can contribute in two ways: 

1. Make a submission to the Pharmacy Board 

You can provide feedback directly to the PBA: 

• Email: PharmBAFeedback@ahpra.gov.au (submission templates and consultation materials are available on the consultation page) 

2. Sign our pro-forma letter and submit it

• Download and sign the AMA letter template (you will need to log in to access the template). This letter can be submitted as is or personalised should you wish to add any further comments. *Note you will need your member log in for both the template and our two page summary of our position, which you can find below. If you have any issues logging in please reach out to memberservices@ama.com.au

Make your voice heard 

This consultation is a key opportunity to ensure that safety, quality, and continuity of care remain central to any changes to prescribing in Australia.